Conference Coverage

ACC Late-Breaking Clinical Trial sessions preview for day 1


Practice-changing science will mark the five Late-Breaking Clinical Trial sessions at the annual meeting of the American College of Cardiology being held in Orlando, March 10-12, according to the meeting’s vice chair, Andrew Kates, MD.

Saturday’s session, held jointly with the Journal of the American College of Cardiology following the Opening Session, will be held from 9 a.m. to 10 a.m. in the Main Tent (Hall C).

Dr. Andrew Kates

Dr. Kates noted in a media webcast that the two trials to be presented on Saturday, ODYSSEY and VEST, “promise to be truly practice changing.”


This will be the second cardiovascular outcomes trial of a proprotein convertase subtilisin/kexin type 9 inhibitor to report its primary outcomes. Last year’s blockbuster FOURIER trial results showed that the PCSK9 inhibitor evolocumab significantly reduced cardiovascular events in patients with stable atherosclerotic cardiovascular disease who were still at residual risk based on elevated LDL cholesterol levels.


Recommended Reading

VIDEO: No short-term link found between PPIs, myocardial infarction
MDedge Cardiology
Abruptio placenta brings increased cardiovascular risk – and soon
MDedge Cardiology
Sex-triggered sudden cardiac arrest extremely rare
MDedge Cardiology
200 cardiovascular drugs now in development
MDedge Cardiology
Young diabetics are at sevenfold increased risk of sudden cardiac death
MDedge Cardiology